Magnetic Seizure Therapy Limits Memory Loss in Bipolar Depression Trial

Balancing Efficacy and Cognitive Preservation in Bipolar Depression

Managing treatment-resistant bipolar depression often requires clinicians to look beyond standard pharmacotherapy toward tertiary neurostimulation techniques [1, 2]. While electroconvulsive therapy remains a highly effective intervention for severe depressive episodes, its clinical application is frequently restricted by concerns regarding cognitive morbidity, particularly the loss of autobiographical memory [3]. Magnetic seizure therapy (a neurostimulation technique that uses high-intensity magnetic fields to induce seizures in a more localized manner than electrical currents) has emerged as a potential alternative designed to spare cognitive function [4]. Although modifications to electrical pulse widths and electrode placements have attempted to reduce side effects, the search for a seizure-based therapy with an improved safety profile continues [5]. A recent randomized pilot trial provides a direct comparison of these modalities to determine if the cognitive advantages of magnetic stimulation can be achieved without sacrificing clinical remission, offering clinicians a potential new tool for patients who cannot tolerate traditional electroconvulsive therapy.

Trial Design and Patient Stratification

The researchers designed a double-blind, randomized, parallel-group pilot clinical trial to evaluate the comparative safety and efficacy of two distinct seizure-induction methods. The study specifically compared right unilateral ultrabrief-pulse electroconvulsive therapy with magnetic seizure therapy in a cohort of patients diagnosed with bipolar depression. While right unilateral ultrabrief-pulse electroconvulsive therapy represents a refined version of traditional treatment intended to reduce side effects by using shorter electrical pulses, magnetic seizure therapy uses magnetic induction to trigger seizures. This magnetic approach aims to limit the electrical field spread to the hippocampus and other memory-sensitive regions, potentially preserving cognitive function. The clinical protocol dictated that participants receive their assigned intervention until they reached clinical remission, discontinued the trial, or completed a maximum of 21 treatments. The researchers defined the primary clinical outcome as remission status determined by the 24-item Hamilton Rating Scale for Depression (a clinician-rated tool used to quantify the severity of depressive symptoms including mood, vegetative signs, and suicidal ideation). To address the primary cognitive outcome, the team utilized the Autobiographical Memory Test to monitor for cognitive adverse effects. This assessment measures a patient's ability to recall specific personal life events, providing a sensitive metric for the retrograde amnesia often associated with convulsive therapies.

Comparative Remission Rates and Clinical Efficacy

The pilot trial enrolled and randomized a total of 55 participants to evaluate the comparative efficacy of the two neurostimulation modalities. Among this initial cohort, 45 participants received an adequate trial of treatment, which the researchers defined as a sufficient number of sessions to assess clinical response or reach the study endpoints. The attrition between randomization and treatment completion reflects the typical challenges of longitudinal neurostimulation studies in a severely depressed patient population. However, the remaining sample provided the necessary data to compare the primary clinical outcomes of magnetic seizure therapy and right unilateral ultrabrief-pulse electroconvulsive therapy. In terms of primary efficacy, 6 out of 20 participants (30%) in the electroconvulsive therapy group achieved clinical remission, as measured by the 24-item Hamilton Rating Scale for Depression. By comparison, 5 out of 25 participants (20%) in the magnetic seizure therapy group reached remission. While the raw percentage was higher in the electroconvulsive therapy arm, the researchers found that the effects on depression symptoms were similar between magnetic seizure therapy and electroconvulsive therapy. This finding suggests that the magnetic approach can induce the necessary therapeutic seizure activity required to alleviate bipolar depression symptoms, even with a more localized induction method. Beyond the primary remission metrics, the study found that secondary clinical outcomes were similar between the electroconvulsive therapy and magnetic seizure therapy groups. These secondary measures reinforced the conclusion that both treatments provide comparable antidepressant benefits. For practicing psychiatrists, these similar efficacy profiles indicate that magnetic seizure therapy may eventually serve as a viable alternative for patients who require robust antidepressant intervention but are highly vulnerable to the cognitive side effects of traditional electrical stimulation.

Quantifying Cognitive Morbidity and Tolerability

The researchers evaluated cognitive morbidity by focusing on autobiographical memory, a domain frequently impaired following neurostimulation. For the purposes of this trial, the authors defined a clinically important worsening in autobiographical memory as a 25% or greater decline in the Autobiographical Memory Test score. Among the participants receiving right unilateral ultrabrief-pulse electroconvulsive therapy, 6 out of 27 participants (22.2%) experienced this level of memory impairment. This incidence highlights the persistent challenge of cognitive adverse effects in clinical practice, even when using ultrabrief-pulse techniques specifically designed to minimize such risks. In contrast, the cohort treated with magnetic seizure therapy demonstrated a more favorable cognitive profile. Only 2 out of 28 participants (7.1%) in the magnetic seizure therapy group met the criteria for clinically important worsening in autobiographical memory. Based on these data, magnetic seizure therapy appeared to result in less worsening of autobiographical memory compared to electroconvulsive therapy. This suggests that the magnetic induction of seizures may better spare the neural circuits involved in personal memory retrieval. Furthermore, the researchers observed that magnetic seizure therapy was better tolerated than electroconvulsive therapy in this patient population. For clinicians, improved tolerability directly translates to better treatment adherence and higher patient acceptance, particularly for individuals who have previously discontinued electroconvulsive therapy due to side effects. While these results highlight a distinct advantage for magnetic seizure therapy in preserving cognitive function, the authors emphasize that the findings are considered preliminary due to the relatively small sample size of the pilot study. With only 55 randomized participants, the study was not powered to provide definitive evidence of superiority. However, the observed reduction in memory decline from 22.2% to 7.1% provides a strong clinical rationale for larger trials to confirm whether magnetic seizure therapy can routinely serve as a safer intervention for patients with bipolar depression.

References

1. Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CH, Young A. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of adult major depressive episodes: A systematic review and network meta-analysis of 113 randomised clinical trials. bioRxiv. 2018. doi:10.1101/426866

2. Tatlı SZ, Atagün Mİ. Rethinking Treatment-Resistant Depression: A Systematic Review of Novel Therapeutic Strategies and Precision Medicine Approaches. Actas espanolas de psiquiatria. 2025. doi:10.62641/aep.v53i6.1946

3. Mathiassen AB, Semkovska M, Lundsgaard C, Gbyl K, Videbech P. Autobiographical memory after electroconvulsive therapy: systematic review and meta-analysis. The British Journal of Psychiatry. 2025. doi:10.1192/bjp.2025.2

4. Chen M, Yang X, Liu C, et al. Comparative efficacy and cognitive function of magnetic seizure therapy vs. electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis. Translational Psychiatry. 2021. doi:10.1038/s41398-021-01560-y

5. Jelovac A, McLoughlin DM. Ultrabrief pulse electroconvulsive therapy for depression: a systematic review and meta-analysis. Molecular Psychiatry. 2025. doi:10.1038/s41380-025-03327-z